March 25, 2014
BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a definitive agreement with the Massachusetts General Hospital (MGH) in Boston, MA to conduct a Phase II clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS), pending FDA and Institutional Review Board approvals. The other two clinical sites slated for the multi-center trial are the University of Massachusetts Memorial (UMass) Hospital and Mayo Clinic. Dana Farber Cancer Institute’s Connell and O’Reilly Cell Manipulation Core Facility will manufacture the NurOwn cells for MGH and UMass Hospital.
“We are excited to be taking the final steps towards FDA approval and the U.S. trial launch,” said Chaim Lebovits, President of BrainStorm. “It is a privilege to be collaborating with Professor Merit Cudkowicz, Chair of Neurology at Massachusetts General Hospital, Professor of Neurology at Harvard Medical School, and leading expert in the field.”
“It is encouraging that stem cell treatments are now in development for people with ALS, and we are eager to begin this trial with BrainStorm’s unique approach,” commented Merit Cudkowicz, M.D., Principal Investigator at MGH.
Find more information here.